Safety information

Indications and clinical use:

EVKEEZA^® (evinacumab for injection) is indicated as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH).

The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.

Contraindications:

EVKEEZA is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.

Relevant warnings and precautions:

• Hypersensitivity and infusion reactions
• Fertility
• Teratogenic risk

Please consult the product monograph at https://evkeeza.ca/hcp/pdfs/Evkeeza_Final_PM.pdf for important information relating to adverse reactions, breastfeeding, drug interactions, and dosing.

The product monograph is also available by calling us at 1-833-388-5872.